Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4715618 | 0.86 | CDK2 (0.35) | TRPV1 | |
| SCHEMBL4715954 | 0.86 | PSEN1 (0.39) | SYKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4716125 | 0.85 | TRPV1 (0.53) | TRPV1ABL1BCR | |
| SCHEMBL4719945 | 0.84 | MAPK10 (0.42) | SYKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4717973 | 0.82 | TRPV1 (0.40) | SYKTRPV1ABL1BCR | |
| SCHEMBL4827208 | 0.82 | KIT (0.42) | SYKABL1BCR | |
| SCHEMBL4717911 | 0.82 | TRPV1 (0.48) | SYKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4715516 | 0.81 | PSEN1 (0.42) | SYKPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL4823991 | 0.81 | PIK3CA (0.41) | SYKABL1BCRMAPK10 | |
| SCHEMBL4718519 | 0.73 | ALDH1A1 (0.40) | CYP2D6TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442701-B2 | Amino-heterocycles as VR-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2008-10-28 | — | — | US | disclosed |
| EP-1562934-B1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME (GB) | 2008-03-26 | — | — | EP | disclosed |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | OPRL1, CNR1, GPR6 | SYK 2522/4885PSEN1 4099/4885PSEN2 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.